| 000 | 01710 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515173159.0 | ||
| 264 | 0 | _c20100202 | |
| 008 | 201002s 0 0 eng d | ||
| 022 | _a1651-226X | ||
| 024 | 7 |
_a10.1080/02841860902974159 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKarlsdottir, Asa | |
| 245 | 0 | 0 |
_aOutcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. _h[electronic resource] |
| 260 |
_bActa oncologica (Stockholm, Sweden) _c2009 |
||
| 300 |
_a874-81 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xblood |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aGonadotropin-Releasing Hormone _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNeoplasms, Hormone-Dependent _xblood |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 | _aRadiotherapy, High-Energy |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMuren, Ludvig Paul | |
| 700 | 1 | _aWentzel-Larsen, Tore | |
| 700 | 1 | _aJohannessen, Dag C | |
| 700 | 1 | _aHaukaas, Svein Andreas | |
| 700 | 1 | _aHalvorsen, Ole Johan | |
| 700 | 1 | _aDahl, Olav | |
| 773 | 0 |
_tActa oncologica (Stockholm, Sweden) _gvol. 48 _gno. 6 _gp. 874-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/02841860902974159 _zAvailable from publisher's website |
| 999 |
_c18913637 _d18913637 |
||